This podcast explores the nuances of rate and rhythm control in atrial fibrillation. The Early Rhythm Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4) Trial that was published in October 2020 will also be discussed.  For today’s debate, Danielle will promote rhythm control while Riley argues that rate control remains the strategy of choice. 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.